Loading
Life sciences · Journal article
Discover Oncology · September 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Bispecific T-cell engagers are Fc-less, Fv-based members of the broader family of T-cell-engaging bispecific antibodies designed to redirect cytotoxic T cells toward tumor cells by simultaneously binding CD3 and tumor-associated antigens. Despite their clinical promise, CD3-engaging bispecific antibody therapies remain limited by cytokine release syndrome (CRS), a systemic inflammatory response triggered by excessive immune activation, and, in the case of canonical Fc-less BiTEs, by short serum half-life. Half-life extension strategies, including Fc- or albumin-based engineering and FcRn-mediated recycling, have therefore become central to next-generation construct design. This review consolidates recent developments in CD3-engaging bispecific antibody engineering, including format optimization, affinity modulation, selectivity enhancement, and half-life prolongation, as well as clinical applications in hematologic and solid malignancies. Toxicity management strategies, including step-up dosing, corticosteroid premedication, and tocilizumab-based CRS management, are emphasized, together with emerging biomarkers that may predict response and adverse events. Furthermore, future directions, including trispecific antibodies, BiTE-CAR hybrids, tumor-selective activation through logic-gated or conditional binding strategies, and biomarker-guided patient selection, are discussed. This article integrates engineering innovations with clinical outcomes and translational challenges to guide the development of next-generation T-cell-engaging bispecific therapeutics.